IDEAYA Biosciences financials
$37.86−0.94%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.9M | $6.6M | $10.9M | $207.8M | $0.00 | $0.00 | $7.0M | $0.00 | $0.00 | $0.00 | $3.9M | $8.0M |
| Gross profit | $8.9M | $6.6M | $10.9M | $207.8M | $0.00 | $0.00 | $7.0M | $0.00 | $0.00 | $0.00 | $3.9M | $8.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — | — | 100.0% | — | — | — | 100.0% | 100.0% |
| Operating income | -$122.3M | -$108.5M | -$94.6M | $108.5M | -$88.8M | -$84.4M | -$144.1M | -$66.9M | -$64.9M | -$51.0M | -$41.9M | -$33.5M |
| Net income | -$112.5M | -$98.5M | -$83.3M | $119.2M | -$77.5M | -$72.2M | -$130.3M | -$51.8M | -$52.8M | -$39.6M | -$34.0M | -$27.4M |
| Net margin | −1269.6% | −1502.1% | −765.7% | 57.4% | — | — | −1861.6% | — | — | — | −865.8% | −341.4% |
| Diluted EPS | $-1.22 | $-1.11 | $-0.95 | $1.33 | $-0.88 | $-0.82 | $-1.49 | $-0.60 | $-0.68 | $-0.53 | $-0.52 | $-0.46 |
| EBITDA | -$121.6M | -$107.9M | -$93.8M | $109.1M | -$88.1M | -$83.8M | -$143.6M | -$66.3M | -$64.3M | -$50.4M | -$41.9M | -$32.9M |
| Operating cash flow | -$88.2M | -$75.2M | -$90.5M | $142.2M | -$62.5M | -$60.3M | -$121.7M | -$49.2M | -$32.9M | -$43.8M | -$23.7M | -$30.2M |
| Free cash flow | -$89.1M | -$76.1M | -$90.8M | $142.2M | -$63.1M | -$61.7M | -$122.8M | -$49.7M | -$33.9M | -$45.1M | -$24.6M | -$30.8M |
| Diluted shares | 92.1M | 88.7M | 87.4M | 89.7M | 88.5M | 88.4M | 87.5M | 86.2M | 78.0M | 75.1M | 65.5M | 60.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $272.6M | $157.5M | $112.8M | $298.9M | $114.6M | $130.0M |
| Short-term investments | $556.4M | $513.7M | $526.6M | $488.0M | $555.1M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.31B | $1.03B | $1.11B | $1.19B | $1.04B | $1.10B |
| Total liabilities | $110.8M | $93.1M | $86.4M | $93.1M | $81.6M | $76.5M |
| Shareholders' equity | $1.20B | $937.3M | $1.02B | $1.09B | $959.7M | $1.02B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology